首页> 外文期刊>Cell cycle >Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer
【24h】

Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer

机译:长度非致RNA SnHG22通过与MicroRNA-429的竞争结合增加Zeb1表达,以促进乳头状甲状腺癌的恶性肿瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Long noncoding RNA termed small nucleolar RNA host gene 22 (SNHG22) is a crucial regulator in epithelial ovarian carcinoma. Nevertheless, the regulatory functions of SNHG22 in papillary thyroid cancer (PTC) progression and its mechanisms of action remain poorly defined. Therefore, the present study aimed to investigate the role of SNHG22 in the malignant phenotype of PTC and determine whether SNHG22 regulates PTC progression via a ceRNA mechanism. SNHG22 expression in PTC was detected using reverse transcription-quantitative polymerase chain reaction analysis. The biological actions of SNHG22 silencing in PTC cells were evaluated both in vitro (using Cell Counting Kit-8 assay, flow cytometry analysis, and cell migration and invasion assays) and in vivo (using tumorigenicity assay). Herein, high SNHG22 expression was observed in PTC tissues and cell lines. This high SNHG22 level was closely associated with unfavorable clinicopathological characteristics and worse overall survival in patients with PTC. SNHG22 knockdown effectively suppressed PTC cell proliferation, migration, and invasion in vitro; accelerated cell apoptosis; and hindered tumor growth in vivo. Mechanistic experiments revealed that SNHG22 directly interacts with microRNA-429 (miR-429) as an miRNA sponge and positively modulates ZEB1 expression. Rescue assays found that miR-429 inhibition or ZEB1 upregulation can offset the actions of SNHG22 knockdown in PTC cells. In sum, SNHG22, miR-429, and ZEB1 form an interactive regulatory network with cancer-promoting roles in PTC cells, suggesting that the SNHG22/miR-429/ZEB1 pathway is a novel diagnostic and therapeutic target.
机译:长的非编码RNA称为小核仁RNA宿主基因22(SNHG22)是上皮性卵巢癌中的关键调节剂。然而,SNHG22在乳头状甲状腺癌(PTC)进展中的调节功能及其作用机制仍然定义不足。因此,本研究旨在探讨SnHG22在PTC的恶性表型中的作用,并确定SNHG22是否通过Cerna机制调节PTC进展。使用逆转录定量聚合酶链反应分析检测PTC中的SNHG22表达。在体外(使用细胞计数试剂盒-8测定,流式细胞术分析和细胞迁移和侵袭和侵袭测定)和体内(使用致瘤性测定)评估SnHG22沉默的生物学作用。这里,在PTC组织和细胞系中观察到高SNHG22表达。这种高SNHG22水平与PTC患者的不利临床病理特征密切相关,较差的整体生存率。 SNHG22敲低有效地抑制了PTC细胞增殖,迁移和侵袭体外;加速细胞凋亡;并阻碍肿瘤生长体内。机械实验表明,SNHG22直接与MicroRNA-429(miR-429)相互作用,作为miRNA海绵,呈正常调节Zeb1表达。抢救试验发现miR-429抑制或Zeb1上调可以抵消SNHG22敲低在PTC细胞中的作用。总之,SNHG22,miR-429和Zeb1形成互动调节网络,其在PTC细胞中促进癌症作用,表明SNHG22 / miR-429 / Zeb1途径是一种新型诊断和治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号